Ken Fisher’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,428
| Closed | -$498K | – | 1238 |
|
|
2023
Q2 | $498K | Hold |
12,428
| – | – | ﹤0.01% | 868 |
|
|
2023
Q1 | $507K | Sell |
12,428
-8,430
| -40% | -$335K | ﹤0.01% | 848 |
|
|
2022
Q4 | $805K | Buy |
20,858
+54
| +0.3% | +$2.63K | ﹤0.01% | 794 |
|
|
2022
Q3 | $1.11M | Hold |
20,804
| – | – | ﹤0.01% | 651 |
|
|
2022
Q2 | $1.21M | Buy |
20,804
+85
| +0.4% | +$5.57K | ﹤0.01% | 602 |
|
|
2022
Q1 | $1.58M | Hold |
20,719
| – | – | ﹤0.01% | 581 |
|
|
2021
Q4 | $1.25M | Sell |
20,719
-68
| -0.3% | -$3.75K | ﹤0.01% | 611 |
|
|
2021
Q3 | $1.16M | Buy |
20,787
+4,847
| +30% | +$279K | ﹤0.01% | 595 |
|
|
2021
Q2 | $967K | Sell |
15,940
-10
| -0.1% | -$633 | ﹤0.01% | 622 |
|
|
2021
Q1 | $1.12M | Sell |
15,950
-1,582
| -9% | -$113K | ﹤0.01% | 599 |
|
|
2020
Q4 | $1.05M | Buy |
17,532
+1,948
| +13% | +$114K | ﹤0.01% | 591 |
|
|
2020
Q3 | $937K | Sell |
15,584
-6,968
| -31% | -$405K | ﹤0.01% | 570 |
|
|
2020
Q2 | $1.18M | Sell |
22,552
-3,565
| -14% | -$149K | ﹤0.01% | 549 |
|
|
2020
Q1 | $876K | Sell |
26,117
-79
| -0.3% | -$3.28K | ﹤0.01% | 552 |
|
|
2019
Q4 | $1.19M | Sell |
26,196
-4,508
| -15% | -$191K | ﹤0.01% | 565 |
|
|
2019
Q3 | $1.17M | Buy |
+30,704
| New | +$1.23M | ﹤0.01% | 601 |
|
|
2018
Q1 | – | Sell |
-5,282
| Closed | -$241K | – | 812 |
|
|
2017
Q4 | $241K | Buy |
+5,282
| New | +$209K | ﹤0.01% | 782 |
|
|
2017
Q3 | – | Sell |
-6,257
| Closed | -$298K | – | 811 |
|
|
2017
Q2 | $298K | Hold |
6,257
| – | – | ﹤0.01% | 653 |
|
|
2017
Q1 | $285K | Buy |
+6,257
| New | +$270K | ﹤0.01% | 635 |
|
|
2016
Q4 | – | Sell |
-6,282
| Closed | -$215K | – | 749 |
|
|
2016
Q3 | $215K | Buy |
6,282
+85
| +1% | +$3.33K | ﹤0.01% | 677 |
|
|
2016
Q2 | $226K | Hold |
6,197
| – | – | ﹤0.01% | 647 |
|
|
2016
Q1 | $400K | Hold |
6,197
| – | – | ﹤0.01% | 584 |
|
|
2015
Q4 | $476K | Buy |
6,197
+247
| +4% | +$14K | ﹤0.01% | 577 |
|
|
2015
Q3 | $245K | Buy |
5,950
+1,150
| +24% | +$70.4K | ﹤0.01% | 612 |
|
|
2015
Q2 | $339K | Hold |
4,800
| – | – | ﹤0.01% | 494 |
|
|
2015
Q1 | $426K | Hold |
4,800
| – | – | ﹤0.01% | 459 |
|
|
2014
Q4 | $426K | Buy |
+4,800
| New | +$454K | ﹤0.01% | 463 |
|
Other funds holding PCRX
FCM
SIMG
PM
Ken Fisher's PCRX Position: Q3 2023 in Review
Ken Fisher sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 12,428 shares — an estimated $498K sold.
Ken Fisher first reported a position in PCRX in Q4 2014 and held it in 27 quarters. The position peaked at $1.58M in Q1 2022. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.
- Ken Fisher reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
- Ken Fisher sold 12,428 Pacira BioSciences shares in Q3 2023, an estimated $498K.
- Ken Fisher first reported a position in Pacira BioSciences in Q4 2014 and held it in 27 quarters.
- Ken Fisher's Pacira BioSciences position peaked at $1.58M in Q1 2022.
- 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.
Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.